368 related articles for article (PubMed ID: 10208431)
1. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
2. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
3. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies.
Kurokawa M; Tanaka T; Tanaka K; Ogawa S; Mitani K; Yazaki Y; Hirai H
Oncogene; 1996 Feb; 12(4):883-92. PubMed ID: 8632911
[TBL] [Abstract][Full Text] [Related]
5. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
Frank R; Zhang J; Uchida H; Meyers S; Hiebert SW; Nimer SD
Oncogene; 1995 Dec; 11(12):2667-74. PubMed ID: 8545124
[TBL] [Abstract][Full Text] [Related]
6. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence.
Kurokawa M; Ogawa S; Tanaka T; Mitani K; Yazaki Y; Witte ON; Hirai H
Oncogene; 1995 Sep; 11(5):833-40. PubMed ID: 7675444
[TBL] [Abstract][Full Text] [Related]
7. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
8. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
9. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.
Yergeau DA; Hetherington CJ; Wang Q; Zhang P; Sharpe AH; Binder M; Marín-Padilla M; Tenen DG; Speck NA; Zhang DE
Nat Genet; 1997 Mar; 15(3):303-6. PubMed ID: 9054947
[TBL] [Abstract][Full Text] [Related]
10. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
11. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
12. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
13. Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias.
Wang J; Wang M; Liu JM
Cancer Res; 1997 Jul; 57(14):2951-5. PubMed ID: 9230207
[TBL] [Abstract][Full Text] [Related]
14. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
[TBL] [Abstract][Full Text] [Related]
15. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
16. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
Kasashima K; Sakota E; Kozu T
Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
[TBL] [Abstract][Full Text] [Related]
17. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
Lenny N; Meyers S; Hiebert SW
Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
Mitani K
Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
[TBL] [Abstract][Full Text] [Related]
19. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.
Erickson PF; Robinson M; Owens G; Drabkin HA
Cancer Res; 1994 Apr; 54(7):1782-6. PubMed ID: 8137293
[TBL] [Abstract][Full Text] [Related]
20. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2.
Kohzaki H; Ito K; Huang G; Wee HJ; Murakami Y; Ito Y
Oncogene; 1999 Jul; 18(28):4055-62. PubMed ID: 10435586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]